TigerOak Management L.L.C. Takes Position in Novartis AG (NYSE:NVS)

TigerOak Management L.L.C. bought a new stake in Novartis AG (NYSE:NVS) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 3,096 shares of the company’s stock, valued at approximately $301,000.

Several other hedge funds and other institutional investors have also made changes to their positions in NVS. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Novartis by 128.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 528,682 shares of the company’s stock valued at $51,554,000 after acquiring an additional 296,890 shares in the last quarter. World Investment Advisors LLC purchased a new stake in Novartis during the third quarter worth about $30,063,000. Fisher Asset Management LLC boosted its holdings in Novartis by 15.7% during the third quarter. Fisher Asset Management LLC now owns 1,706,009 shares of the company’s stock worth $196,225,000 after buying an additional 231,851 shares in the last quarter. Mediolanum International Funds Ltd purchased a new stake in Novartis during the third quarter worth about $24,096,000. Finally, ABC Arbitrage SA purchased a new stake in Novartis during the fourth quarter worth about $19,795,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Stock Performance

NYSE:NVS opened at $105.43 on Friday. The firm has a 50 day simple moving average of $100.70 and a 200-day simple moving average of $108.30. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.90. The firm has a market cap of $215.50 billion, a PE ratio of 17.93, a P/E/G ratio of 1.70 and a beta of 0.58. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. On average, equities analysts expect that Novartis AG will post 8.42 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on NVS shares. StockNews.com raised shares of Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 8th. Morgan Stanley started coverage on shares of Novartis in a report on Wednesday. They set an “underweight” rating on the stock. UBS Group reissued a “neutral” rating on shares of Novartis in a report on Thursday. BMO Capital Markets lifted their target price on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.